Who
Vijay Satyanand Pande
Director
Company insider
Files Form 4 as: Director, BioAge Labs; Director, Nautilus Biotechnology.
In numbers
- Trades disclosed
- 18
- Buys
- 4
- Sells
- 0
- Bought
- $20.5M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 15 Jun 2022
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 7 Aug 2025filed 11 Aug 2025 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 3 Oct 2024filed 3 Oct 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Bought | $504K25,306 at $19.90 | filing |
| 2 Oct 2024filed 3 Oct 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Bought | $1.3M67,096 at $19.73 | filing |
| 1 Oct 2024filed 3 Oct 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Bought | $2.5M126,793 at $19.73 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,819,863 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,843,502 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —846,152 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,924,318 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code C | —855,972 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code C | —413,100 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code C | —189,609 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code C | —655,294 | filing |
| 27 Sep 2024filed 27 Sep 2024 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Bought | $16.2M900,000 at $18.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 15 Jun 2022filed 16 Jun 2022 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —86,467 at $0.00 | filing |
News
BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026
0 headlines in the last 90 days name Vijay Satyanand Pande; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.